We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three se... Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines. Show more
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms...
U.S. index futures surged in pre-market trading on Wednesday, driven by expectations of a Donald Trump victory and Republican control of Congress, which could benefit companies through his tax...
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying...
Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscienceData show TEV-'749 drug delivery...
Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupportedThe company intends...
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
BP Plc (NYSE:BP) – BP expects a net debt increase in Q3 due to lower refining margins and changes in asset sale timing. The company faces reduced earnings of up to $600 million, signaling a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.6 | -3.40328984685 | 17.63 | 17.86 | 16.94 | 7448336 | 17.2613467 | DR |
4 | -1.05 | -5.80752212389 | 18.08 | 19.055 | 16.94 | 6465093 | 17.92347604 | DR |
12 | -1.1 | -6.06729178158 | 18.13 | 19.08 | 16.94 | 6482395 | 17.97932641 | DR |
26 | 0.12 | 0.709639266706 | 16.91 | 19.08 | 15.62 | 8014598 | 17.32547623 | DR |
52 | 8.12 | 91.1335578002 | 8.91 | 19.08 | 8.64 | 9048991 | 14.63425595 | DR |
156 | 7.54 | 79.4520547945 | 9.49 | 19.08 | 6.7791 | 9902137 | 10.5588352 | DR |
260 | 7.25 | 74.1308793456 | 9.78 | 19.08 | 6.25 | 10476483 | 10.46100561 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions